Core Diagnostics announced the launch of its operations in India, at a mini conference held at The Oberoi in New Delhi. The conference, attended by over 150 top clinicians from around the country focused on a new generation of high-end diagnostic tests that help with disease stratification and therapy selection. Dr Mark Pegram of Stanford University School of Medicine, Dr Mahul Amin of Cedars Sinai Medical Center in Los Angeles, and Dr Ashok Seth of Fortis were the keynote speakers who spoke from three different perspectives – of an oncologist, a pathologist, and a cardiologist.
Core Diagnostics, co-founded by Zoya Brar, and Arghya Basu recently merged with the Palo Alto, US-based OncoMDx, founded by entrepreneur Mohan Uttarwar. The recently formed company has secured Rs 27 crore financing from Artiman Ventures, based in Silicon Valley and Bangalore.
“Effective treatment for any disease begins with an accurate and timely diagnosis. While India has made tremendous progress in Healthcare over the past decade, we lag behind the Western world when it comes to diagnostics. Our aim at CORE is to bridge the diagnostic deficit,” said Mohan Uttarwar, who will serve as the CEO of the global company.
“These tests bring personalised medicine one step closer to reality and can help the pathologist provide the most actionable information to the oncologists, cardiologists, and other specialists,” said Ajit Singh, Partner at Artiman Ventures, and Consulting Professor at Stanford University, who also serves as the lead Director on the Board of Max Healthcare.
Ramesh Radhakrishnan, Partner at Artiman believes that India is fast becoming the platform for broad-based innovations, especially in life science and healthcare.
EH News Bureau